The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 178 of the 179 references it cites were found in a registry or an index.
Abstract
Cholinergic synapses are ubiquitous in the human central nervous system. Their high density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic transmission is likely to be critically important for memory, learning, attention and other higher brain functions. Several lines of research suggest additional roles for cholinergic systems in overall brain homeostasis and plasticity. As such, the brain's cholinergic system occupies a central role in ongoing research related to normal cognition and age-related cognitive decline, including dementias such as Alzheimer's disease. The cholinergic hypothesis of Alzheimer's disease centres on the progressive loss of limbic and neocortical cholinergic innervation. Neurofibrillary degeneration in the basal forebrain is believed to be the primary cause for the dysfunction and death of forebrain cholinergic neurons, giving rise to a widespread presynaptic cholinergic denervation. Cholinesterase inhibitors increase the availability of acetylcholine at synapses in the brain and are one of the few drug therapies that have been proven clinically useful in the treatment of Alzheimer's disease dementia, thus validating the cholinergic system as an important therapeutic target in the disease. This review includes an overview of the role of the cholinergic system in cognition and an updated understanding of how cholinergic deficits in Alzheimer's disease interact with other aspects of disease pathophysiology, including plaques composed of amyloid-β proteins. This review also documents the benefits of cholinergic therapies at various stages of Alzheimer's disease and during long-term follow-up as visualized in novel imaging studies. The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The FDA approved two anti-amyloid immunotherapies, lecanemab and donanemab, for “early-stage” AD, encompassing both stage 3 (MCI) and stage 4 (mild dementia).”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [18]
In the citing paper
“Degeneration of cholinergic neurons is known to significantly contribute to cognitive decline in AD patients [132] and has been studied in a variety of genetic AD mouse models.”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [132]
In the citing paper
“AChE contributes to acetylcholine depletion and may facilitate the formation of neurotoxic Aβ-AChE complexes38.”
From Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer’s disease models (2026) · cites this paper as [38]
In the citing paper
“Cholinergic deficit also alters the permeability of the blood brain barrier causing erroneous transportation of metabolites and hampering the removal of amyloid plaque, worsening the disease condition [8].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [8]
In the citing paper
“From this point of view, AD could be prevented or effectively treated by decreasing the production of Aβ and tau; preventing aggregation or misfolding of these proteins; neutralizing or removing the toxic aggregate or misfolded forms of these proteins; or a combination of these modalities.7”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [7]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., & Perry, R. H. (1978) · BMJ · doi:10.1136/bmj.2.6150.1457 · Cited by 2,042
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Human Memory and the Cholinergic System: A Relationship to Aging?
Drachman, D. A. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490320001001 · Cited by 1,397
NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311
Research works printed but not linked: 1
- Geula, 1994, Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease, 263
Cited by
Items 801–900 of 1,002
Yang, F., Zhang, N., Ou, G., & Xu, S.-W. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.5 · Cited by 12
Ding, N., Meng, H., Wu, C., Hong, H., Luo, Y., & Tan, Y. (2023) · Food Bioscience · doi:10.1016/j.fbio.2023.103460 · Cited by 12
Saffour, S., Evren, A. E., Sağlık, B. N., & Yurttaş, L. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673333159240815061359 · Cited by 12
Wang, L., Lu, Z., Teng, Y., Pan, W., Li, Y., Su, S., Chang, J., & Zhao, M. (2023) · The FASEB Journal · doi:10.1096/fj.202301699rr · Cited by 12
Cao, Z., Mai, Y., Fang, W., Lei, M., Luo, Y., Zhao, L., Liao, W., Yu, Q., Xu, J., Ruan, Y., et al. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.760360 · Cited by 12
Kandy, A. T., Venkatesan, R., Mohan, D., Ismail, S. C., Jupudi, S., & Selvaraj, D. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03410-8 · Cited by 12
Qiu, T., Zeng, Q., Luo, X., Xu, T., Shen, Z., Xu, X., Wang, C., Li, K., Huang, P., Li, X., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.755630 · Cited by 12
Xue, S., Li, M., Leng, B., Yao, R., Sun, Z., Yang, Y., Gao, Y., Liu, X., Sun, H., Li, Z., et al. (2022) · SLEEP · doi:10.1093/sleep/zsac146 · Cited by 12
Akarsu, G. D., & Çetin, A. (2022) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000525617 · Cited by 12
Zholos, A. V., Moroz, O. F., & Storozhuk, M. (2018) · Current Molecular Pharmacology · doi:10.2174/1874467211666181012150847 · Cited by 12
Moss, D. E. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190626 · Cited by 12
Nipecotic Acid Derivatives as Potent Agents against Neurodegeneration: A Preliminary Study
Papagiouvannis, G., Theodosis‐Nobelos, P., & Rekka, E. A. (2022) · Molecules · doi:10.3390/molecules27206984 · Cited by 12
Pires, A. F. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.59.2022.tde-06052022-103953 · Cited by 12
Wang, L., Du, C., Liu, H., Qiu, W., Lü, X., Hu, Y., Li, Y., Sun, T., Chen, Y., & Sun, H. (2022) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202100910 · Cited by 12
Azman, E. M., Ghazali, H. M., Karim, R., & Zare, D. (2021) · Food Research · doi:10.26656/fr.2017.5(2).583 · Cited by 12
Bidirectional Crosstalk between the Heart and Brain in Alzheimer's Disease
Wang, Z., Zhou, L., Zhao, N., Zhang, Z., Zhang, J., & Ren, Q. (2024) · Aging and Disease · doi:10.14336/ad.2024.1132 · Cited by 12
Boiangiu, R. Ş., Bağcı, E., Dumitru, G., Hriţcu, L., & Todirașcu-Ciornea, E. (2023) · Plants · doi:10.3390/plants12040784 · Cited by 12
Rowan, M. T., Alharthi, A. A., Noel-Storr, A. H., Myint, P. K., Stewart, C., McCleery, J. M., & Quinn, T. J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015405 · Cited by 11
Recent Advancements in Strategies for Abnormal Protein Clearance in Alzheimer's Disease
Zhuang, J., Gao, J., Yin, Y., Gong, B., Ji, W., Chen, X., Li, P., Cheng, W., Zhao, Y., & He, B. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220214092824 · Cited by 11
Application of Natural Products in Neurodegenerative Diseases by Intranasal Administration: A Review
Jin, Y., Ma, X., Liu, S., Zong, S., Cheng, Y., Zhang, H., Wang, C., & Li, Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050675 · Cited by 11
Hirota, Y., Sakakibara, Y., Takei, K., Nishijima, R., Sekiya, M., & Iijima, K. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230121 · Cited by 11
Argentati, C., Tortorella, I., Bazzucchi, M., Emiliani, C., Morena, F., & Martino, S. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030115 · Cited by 11
Simões, J. L. B., Sobierai, L. D., Leal, I. F., dos Santos, M. V. R., Coiado, J. V., & Bagatini, M. D. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.12.007 · Cited by 11
Alzheimer's disease: from molecular pathways to therapies
Feng, J.-Q., Yang, L.-L., Ya-xi, L., & Yao, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00443-2 · Cited by 11
Olivé, I., Makris, N., Densmore, M., McKinnon, M. C., & Lanius, R. A. (2021) · Human Brain Mapping · doi:10.1002/hbm.25454 · Cited by 11
Xu, Y., Zhang, S., Sun, Q., Wang, X., Chai, Y.-N., Mishra, C. K., Chandra, S. R., & Ai, J. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.586591 · Cited by 11
Gopalan, D., Patil, P. H., Channabasavaiah, J. P., Kini, S. G., Alex, A. T., Udupa, N., & Mutalik, S. (2022) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2022.120606 · Cited by 11
Svobodová, B., Moravcová, Z., Misiachna, A., Nováková, G., Marek, A., Finger, V., Odvarkova, J., Pejchal, J., Karasová, J. Ž., Netolický, J., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117678 · Cited by 11
Path integration impairments reveal early cognitive changes in subjective cognitive decline
Segen, V., Kabir, M. R., Streck, A., Slavík, J., Glanz, W., Butryn, M., Newman, E. L., Tiganj, Z., & Wolbers, T. (2025) · Science Advances · doi:10.1126/sciadv.adw6404 · Cited by 11
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2024) · Molecules · doi:10.3390/molecules29245936 · Cited by 11
Rubido, N., Riedel, G., & Vuksanović, V. (2023) · Brain Communications · doi:10.1093/braincomms/fcad320 · Cited by 11
Stulz, S. B., Castro, S., Dumont, G., Gutkin, B. S., & Battaglia, D. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.31.596792 · Cited by 11
Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System
Dávila, G., Torres‐Prioris, M. J., López-Barroso, D., & Berthier, M. L. (2023) · CNS Drugs · doi:10.1007/s40263-023-01017-4 · Cited by 11
CHRNA5 links chandelier cells to severity of amyloid pathology in aging and Alzheimer’s disease
Rybnicek, J., Chen, Y., Milic, M. S., Tio, E. S., McLaurin, J., Hohman, T. J., Jager, P. L. D., Schneider, J. A., Wang, Y., Bennett, D. A., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02785-3 · Cited by 11
Guo, C., Valdés, A., Sánchez-Martínez, J. D., Ibáñez, E., Bi, J., & Cifuentes, A. (2022) · Foods · doi:10.3390/foods11162464 · Cited by 11
Xi, M., Feng, C., Du, K., Lv, W., Du, C., Shen, R., & Sun, H. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128602 · Cited by 11
Rahmatkar, S. N., & Singh, D. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04776-x · Cited by 11
Eciroglu, H., Çelik, P. A., Kelicen‐Uğur, P., & Dönmez‐Altuntaş, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05082-2 · Cited by 11
New Synthetic Caffeine Analogs as Modulators of the Cholinergic System
Fabiani, C., Biscussi, B., Munafó, J. P., Murray, A. P., Corradi, J., & Antollini, S. S. (2021) · Molecular Pharmacology · doi:10.1124/molpharm.121.000415 · Cited by 11
Weinstein, J. J., Moeller, S. J., Perlman, G., Gil, R. B., Snellenberg, J. X. V., Wengler, K., Meng, J., Slifstein, M., & Abi‐Dargham, A. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.01.019 · Cited by 11
Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson’s Disease
Hsu, Y.-F., Lin, S., Chu, Y., Tsai, Y., Huang, J., Phoa, F. K. H., & Wu, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063554 · Cited by 11
Xie, B., Yang, S., Hao, Y., Sun, Y., Li, L., Guo, C., & Yu, Y. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106483 · Cited by 11
Vashisth, M. K., Hu, J., Liu, M., Basha, S. H., Chen, Y., & Huang, W. (2024) · Scientific Reports · doi:10.1038/s41598-024-78975-2 · Cited by 11
Abderrezag, N., Sánchez-Martínez, J. D., Louaer, O., Méniai, A.-H., & Mendiola, J. A. (2021) · Molecules · doi:10.3390/molecules26226951 · Cited by 11
Stępnik, K. E., Kukuła‐Koch, W., Boguszewska‐Czubara, A., & Gaweł, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074021 · Cited by 11
El–Akabawy, G., Aabed, K., Rashed, L. A., Amin, S. N., Alsaati, I., & Alfayez, M. A. (2022) · Folia Morphologica · doi:10.5603/fm.a2021.0073 · Cited by 11
Gürsoy, Ş., Satici, D., Kuzu, B., Türkmenoğlu, B., Dilek, E., & Algül, Ö. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202400918 · Cited by 11
Thu, D. K., Hong, S., Dao, V. T., Nguyen, T.-D., Nguyen, K. V., Nguyen, H. T., Ullah, S., Tran, T. H., & Kim, S. Y. (2022) · Phytotherapy Research · doi:10.1002/ptr.7602 · Cited by 11
Natural products as a source of cholinesterase inhibitors
de Oliveira, P. C. O., da Silva, G. M., Cass, Q. B., de Moraes, M. C., & Cardoso, C. L. (2024) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2024.100099 · Cited by 11
The Central Cholinergic Synapse: A Primer
Klein, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199670 · Cited by 11
Jamadagni, S. B., Ghadge, P. M., Tambe, M. S., Marimuthu, S., Prasad, G. P., Jamadagni, P. S., Prasad, S. B., Pawar, S. D., Gurav, A. M., Gaidhani, S. N., et al. (2023) · Pharmacognosy Magazine · doi:10.1177/09731296221145063 · Cited by 11
Xie, Y., Liu, L., Zheng, J., Shi, K., Ai, W., Zhang, X., Wang, P., Lan, Z., & Chen, L. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116400 · Cited by 11
Odenkirk, M. T., Zheng, X., Kyle, J. E., Stratton, K. G., Nicora, C., Bloodsworth, K., McLean, C., Masters, C. L., Monroe, M. E., Doecke, J. D., et al. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00604 · Cited by 11
Varma, M. E., Shravage, B. V., Tayade, S. B., Kumbhar, A. S., Butcher, R. J., Jani, V., Sonavane, U., Joshi, R., & Kulkarni, P. P. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130265 · Cited by 11
Ahmad, A. (2023) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2023/5248127 · Cited by 11
Dendrobium nobile Lindl ameliorates learning and memory deficits in scopolamine-treated mice
Zhang, Q., Li, Y., Fan, B., Wang, F., Li, Z., Dias, A. C. P., 刘新民, & Wang, Q. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117416 · Cited by 11
Rao, K. Y., Basha, S. J., Kallubai, M., Gajula, N. N., Sivakumar, I., Kumar, S., Vadde, R., Aramati, B. M. R., Subramanyam, R., & Damu, A. G. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2203255 · Cited by 11
Aljuaid, A., Abdulaziz, O., Allahyani, M. A., Almehmadi, M. M., Alzahrani, A. Y. A., Verma, S., Yusuf, M., & Asif, M. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273315412241009092249 · Cited by 11
Mahmood, M., Hussain, Z., Ullah, M. Z., Ejaz, S. A., Fayyaz, A., Rashid, U., Iqbal, J., & Mumtaz, A. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138760 · Cited by 11
Shen, Y. H. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-d9d92 · Cited by 11
Xu, P., & Shen, M. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117315 · Cited by 11
Calva, J., Cuenca, M. B., León, A., & Benítez, Á. (2025) · Molecules · doi:10.3390/molecules30132712 · Cited by 11
Lisa-Molina, J., Murillo, P. G., Arellano-Martín, I., Jiménez, C., Rodríguez-Escobar, M. L., Tallini, L. R., Viladomat, F., Torras‐Claveria, L., & Bastida, J. (2023) · Molecules · doi:10.3390/molecules28031239 · Cited by 11
Greeley, D. R., Nash, M., Herskowitz, B., Kim, F., Rock, J., Prins, N., Kim, S., Xi, T., Busam, J. A., Tete, B., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100337 · Cited by 10
Wang, M., Zhang, L., Huang, W., Huang, J., Luo, Y., & Huang, N. (2025) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2025.103222 · Cited by 10
Design and synthesis of benzyl aminocoumarin and its anti-Alzheimer's activity
Zhang, Q., Hao, C., Miao, Y., Yun, Y., Sun, X., Pan, Y., Sun, J., & Wang, X. (2021) · New Journal of Chemistry · doi:10.1039/d1nj02950a · Cited by 10
The cholinergic basal forebrain and its role in neurodegeneration
Cykowski, M. D., & Masdeu, J. C. (2025) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaf112 · Cited by 10
Murayama, M. A. (2023) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.22-0164 · Cited by 10
Exploring the mechanisms of chrysin in combating Alzheimer's disease: therapeutic perspectives
Singh, T. G., SHARMA, A. K., & Devi, S. (2024) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2024.162341 · Cited by 10
Unraveling the dual role of ADAM10: Bridging the gap between cancer and Alzheimer’s disease
Alexandre-Silva, V., & Cominetti, M. R. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111928 · Cited by 10
Nazmi, A., Griffin, É. W., Field, R. H., Doyle, S., Hennessy, E., O’Donnell, M., Rehill, A. M., McCarthy, A. W., Healy, D., Doran, M. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.18.427123 · Cited by 10
Mendivil‐Perez, M., Velez‐Pardo, C., Lopera, F. J., Kosik, K. S., & Jiménez-Del-Río, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108957 · Cited by 10
Alsenani, F. (2024) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2024.103998 · Cited by 10
Liu, W., Li, Y., Qin, W., Wang, X., Li, W., Li, Y., Initiative, A. D. N., & Jia, J. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70193 · Cited by 10
Kim, J. H., He, M. T., Kim, M. J., Park, C. H., Lee, J. Y., Shin, Y. S., & Cho, E. J. (2020) · Korean Journal of Medicinal Crop Science · doi:10.7783/kjmcs.2020.28.2.85 · Cited by 10
Monoamines and their Derivatives on GPCRs: Potential Therapy for Alzheimer’s Disease
Farfán‐García, E. D., Márquez-Gómez, R., Barrón‐González, M., Pérez‐Capistran, T., Rosales‐Hernández, M. C., Pinto‐Almazán, R., & Soriano-Ursua, M. A. (2019) · Current Alzheimer Research · doi:10.2174/1570159x17666190409144558 · Cited by 10
Mitochondria and Alzheimer’s Disease: An Electron Microscopy Study
Balogiannis, S. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84881 · Cited by 10
Feng, J., Liu, W., Feng, D., Chitrakar, B., Chen, X., Sang, Y., & Wang, X. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106441 · Cited by 10
Multiple Roles of Paeoniflorin in Alzheimer’s Disease
Meng, Z., Chen, H., Deng, C., & Meng, S. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/2464163 · Cited by 10
Tavares, J., Oliveira, A. V., Nascimento, T. D. S., Gomes, J. M. P., Parente, A. C. B., Bezerra, J. R., da Costa, M. D. R., Soares, M. S. P., Sampaio, T. L., Lima, F. A. V., et al. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01477-7 · Cited by 10
Marcucci, C., Rademacher, M., Kamecki, F., Pastore, V., Bach, H. G., Ricco, R. A., Wagner, M. L., Knez, D., Gobec, S., Colettis, N. C., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16010129 · Cited by 10
Abdelbaset, S., Ayoub, I. M., Mohamed, O. G., Tripathi, A., Eldahshan, O. A., & El‐Kersh, D. M. (2024) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-024-04520-3 · Cited by 10
Akyürek, T. U., Orhan, İ. E., Şenol, F. S., Eren, G., Acar, B., & Şen, A. (2024) · Pharmaceuticals · doi:10.3390/ph17111441 · Cited by 10
Zhang, X., Ma, X., Zhang, J., Nie, H., Mu, G., & Wu, X. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c01742 · Cited by 10
Khan, S., Hussain, R., Iqbal, T., Khan, Y., Jamal, U., Darwish, H. W., & Adnan, M. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2366159 · Cited by 10
Xu, M. Q., Zhang, L., Li, P., Wang, C., & Shi, Y. (2020) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2020.04.002 · Cited by 10
Pouramiri, B., Abbasi, M., & Hadadianpour, E. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202401005 · Cited by 10
Godinez, J., Lee, C. Y., & Schwans, J. P. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129392 · Cited by 10
Jiang, X., Guo, J., Zhang, C., Gu, J., Zhou, T., Bai, R., & Xie, Y. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1978081 · Cited by 10
Pradhan, S. P., Behera, A., & Sahu, P. K. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105907 · Cited by 10
Neuropharmacological and Cognitive Effects of Celastrus paniculatus – A Comprehensive Review
Bhagya, V. R., & Jaideep, S. (2020) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2020.v65i01.013 · Cited by 10
Amyloid β and Alzheimer’s Disease: Molecular Updates from Physiology to Pathology
Giuffrida, M. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097913 · Cited by 10
Persistent Firing in Hippocampal CA1 Pyramidal Cells in Young and Aged Rats
Brahimi, Y., Knauer, B., Price, A. T., Valero-Aracama, M. J., Reboreda, A., Sauvage, M. M., & Yoshida, M. (2023) · eNeuro · doi:10.1523/eneuro.0479-22.2023 · Cited by 10
Zhou, M., Zheng, L. P., Feng, S., Li, X., & Zhao, M. (2025) · Food Chemistry · doi:10.1016/j.foodchem.2025.145667 · Cited by 10
Chik, M. W., Affandi, M. M. R. M. M., Hazalin, N. A. M. N., & Singh, G. K. S. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01560-7 · Cited by 10
Discovery of carbamate-based salicylic acid derivatives as novel cholinesterase inhibitor
Wang, Y., Long, L., Yu, Q., Zhang, H., Li, X., Zhuo, L., Wang, S., & Wang, Z. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134804 · Cited by 10
Vanessa, V. V., Teh, S. S., Lam, K. W., & Mah, S. H. (2022) · Natural Product Research · doi:10.1080/14786419.2022.2137800 · Cited by 10
Naringin and Naringenin: Potential Multi-Target Agents for Alzheimer’s Disease
Lu, J., Chen, J., Li, S., Pan, G.-J., Ou, Y., Yuan, L.-F., Jiang, J., Zeng, L., & Zhao, J. J. (2024) · Current Medical Science · doi:10.1007/s11596-024-2921-z · Cited by 9
The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson’s Disease
Orso, B., Arnaldi, D., Peira, E., Famà, F., Giorgetti, L., Girtler, N. G., Brugnolo, A., Mattioli, P., Biassoni, E., Donniaquio, A., et al. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223308 · Cited by 9
Zhou, M., Tang, S., Zhang, Y., Fu, G., Yu, W., Wang, S., Cheng, S., & Zhenyan, S. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157738 · Cited by 9
Metadata
- Authors
- Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., & Khachaturian, Z. S.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Northwestern University (US)
- McGill University (CA)
- Indiana University School of Medicine (US)
- University Hospital of Geneva (CH)
- Saint Louis University (US)
- Prevent Alzheimer’s Disease 2020 (US)
- University of Rhode Island (US)
- Corresponding author
- Hampel, Harald
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-05-29
- Volume
- 141
- Issue
- 7
- Pages
- 1917-1933
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6022632
- OpenAlex
- W2805257646
- Cited by
- 1,918
- References
- 179
- Citations by year
- 2026: 245 · 2025: 298 · 2024: 298 · 2023: 328 · 2022: 300 · 2021: 228 · 2020: 130 · 2019: 65 · 2018: 21
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- AXA Research Fund
- ‘Fondation pour la Recherche sur Alzheimer’, Paris, France. Ce travail a bénéficié d'une aide de l’Etat ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- Canadian Institutes of Health Research
- National Research Council
- Alzheimer Society of Canada
- Rotary Club Livorno ‘Mascagni’/The Rotary Foundation (GG1758249)
- ADC (AG013854)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic system, cholinergic hypothesis, cholinesterase inhibitors, acetylcholine, cholinergic denervation, neurofibrillary degeneration, amyloid plaques, cognitive decline, cholinergic drugs, combination therapy
- MeSH terms
- Alzheimer Disease, Cholinesterase Inhibitors, Cognition, Cognition Disorders, Humans, Amyloid beta-Peptides, Neurofibrillary Tangles, Cholinergic Agents, Cholinergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.